CEL-SCI Corp. (CVM)

3.50
0.05 1.40
AMEX : Health Technology
Prev Close 3.45
Open 3.46
Day Low/High 3.45 / 3.55
52 Wk Low/High 1.30 / 3.69
Volume 127.07K
Avg Volume 267.50K
Exchange AMEX
Shares Outstanding 17.50M
Market Cap 58.61M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI To Present Today At The 8th Annual LD Micro Invitational

CEL-SCI To Present Today At The 8th Annual LD Micro Invitational

CEL-SCI Corporation (NYSE American: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting today, June 5, 2018 at 12:00 pm PT / 3:00 pm ET at the 8th annual LD Micro Invitational.

CEL-SCI Corporation To Present At The 8th Annual LD Micro Invitational

CEL-SCI Corporation To Present At The 8th Annual LD Micro Invitational

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy biopharmaceutical company, today announced that it will be presenting at the 8th annual LD Micro Invitational on Tuesday, June 5 at 12:00 PM ET.

CEL-SCI Corporation Reports Second Quarter Fiscal 2018 Financial Results

CEL-SCI Corporation Reports Second Quarter Fiscal 2018 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2018.

CEL-SCI Corporation Announces Upcoming Investor Conference Presentations

CEL-SCI Corporation Announces Upcoming Investor Conference Presentations

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy biopharmaceutical company, announces today that Geert Kersten, Chief Executive Officer, will present at the following conferences: 2018 Disruptive Growth & Healthcare...

CEL-SCI Corporation Issues Letter To Shareholders

CEL-SCI Corporation Issues Letter To Shareholders

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

CEL-SCI Announces Adjustment To Warrant Exercise Price

CEL-SCI Announces Adjustment To Warrant Exercise Price

CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol "CVM WS" on the NYSE American have been repriced to $1.

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to July 1, 2018 (close of business).

CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results

CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2017.

CEL-SCI To Present Tomorrow At 2018 BIO CEO & Investor Conference

CEL-SCI To Present Tomorrow At 2018 BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE American: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.

CEL-SCI To Present At 2018 BIO CEO & Investor Conference

CEL-SCI To Present At 2018 BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE American: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.

U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology

U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology

CEL-SCI Corporation (NYSE American: CVM) today announced the U.S.

IIROC Trading Resumption - CVM

IIROC Trading Resumption - CVM

IIROC Trading Halt - CVM

IIROC Trading Halt - CVM

CEL-SCI Announces Adjustment To Warrant Exercise Price

CEL-SCI Announces Adjustment To Warrant Exercise Price

CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol "CVM WS" on the NYSE American have been repriced to $3.

CEL-SCI Awarded Patent For LEAPS Vaccine In Treatment Of Rheumatoid Arthritis

CEL-SCI Awarded Patent For LEAPS Vaccine In Treatment Of Rheumatoid Arthritis

CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent EP 2254588B1 titled, "Method of Preparation and Composition of Peptide Constructs for Treatment of...

CEL-SCI Issues Letter To Shareholders

CEL-SCI Issues Letter To Shareholders

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

CEL-SCI Reports Fiscal 2017 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2017 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE American: CVM) reported financial results today for the fiscal year ended September 30, 2017.

CEL-SCI Announces Robert Watson Joins Its Board Of Directors

CEL-SCI Announces Robert Watson Joins Its Board Of Directors

CEL-SCI Corporation ( NYSE American: CVM) announced today that healthcare information technology executive Robert Watson has joined the Company's Board of Directors.

CEL-SCI Reaches Full Enrollment In Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Reaches Full Enrollment In Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Corporation ( NYSE American: CVM) announced today that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte...

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Corporation ( NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine*...

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016

CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to March 1, 2018 (close of business).

CEL-SCI Announces Update On Arbitration Against Former Clinical Research Organization

CEL-SCI Announces Update On Arbitration Against Former Clinical Research Organization

CEL-SCI Corporation ( NYSE American:CVM) announced today an update on its arbitration with its former clinical research organization (CRO).

CEL-SCI Granted European Patent For Multikine's Mechanism Of Action In Making Tumors 'Visible' To The Immune System

CEL-SCI Granted European Patent For Multikine's Mechanism Of Action In Making Tumors 'Visible' To The Immune System

CEL-SCI Corporation ( NYSE American: CVM ) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection),...

CEL-SCI Announces Update On Ongoing Arbitration Against Former Clinical Research Organization

CEL-SCI Announces Update On Ongoing Arbitration Against Former Clinical Research Organization

CEL-SCI Corporation ( NYSE American: CVM ) announced today that as it nears the conclusion of its arbitration with its former clinical research organization (CRO), the Company has restructured its agreement with the...

CEL-SCI Announces $1.5 Million NIH SBIR Grant To Support Development Of Rheumatoid Arthritis Vaccine

CEL-SCI Announces $1.5 Million NIH SBIR Grant To Support Development Of Rheumatoid Arthritis Vaccine

CEL-SCI Corporation ( NYSE American: CVM ) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin...

CEL-SCI To Present Today At The 19th Annual Rodman & Renshaw Global Investment Conference

CEL-SCI To Present Today At The 19th Annual Rodman & Renshaw Global Investment Conference

CEL-SCI Corporation (NYSE American: CVM), announces Geert Kersten, Chief Executive Officer, will present today at the 19th Annual Rodman & Renshaw Global Investment Conference at 2:10 PM.

CEL-SCI To Present At The 19th Annual Rodman & Renshaw Global Investment Conference On September 11, 2017

CEL-SCI To Present At The 19th Annual Rodman & Renshaw Global Investment Conference On September 11, 2017

CEL-SCI Corporation (NYSE American: CVM), today announced Geert Kersten, Chief Executive Officer, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.

TheStreet Quant Rating: D (Sell)